<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01074073</url>
  </required_header>
  <id_info>
    <org_study_id>D1050247</org_study_id>
    <nct_id>NCT01074073</nct_id>
  </id_info>
  <brief_title>Lithium Drug-Drug Interaction Study With Lurasidone HCl</brief_title>
  <official_title>A Phase 1, Open-Label, 2-Period, Sequential, Drug-Drug Interaction Study To Determine The Effect Of Lithium 600 Mg BID On The Safety And Pharmacokinetics Of Lurasidone 120 Mg QD In Patients With Schizophrenia Or Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the drug-drug interaction effect between Lithium and
      Lurasidone HCl.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the steady state pharmacokinetic profile of lurasidone 120 mg QD when administered
      alone vs. the steady state pharmacokinetic profile of lurasidone 120 mg QD when
      coadministered with steady state lithium 600 mg BID.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Lithium/Lurasidone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Schizophrenia Patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone HCl</intervention_name>
    <description>lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).
Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).
On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast.</description>
    <arm_group_label>Lithium/Lurasidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform.

          2. Females who participate in this study:

               -  are unable to have children-OR-

               -  are willing to remain abstinent from Day -5 until 90 days after discharge;

          3. Males must be willing to remain sexually abstinent or use an effective method of birth
             control (e.g. condom) from Day -5 until 90 days after discharge.

          4. Able and agree to remain off of prior antipsychotic medication for the duration of the
             study.

        Exclusion Criteria:

          1. Presence or history (within the last year) of a medical or surgical condition (e.g.
             gastrointestinal disease) that might interfere with the absorption, metabolism, or
             excretion of orally administered lurasidone.

          2. Positive test results within 30 days prior to the start of the study for:

          3. Participated in another clinical trial or receiving an investigational product within
             30 days prior to drug administration.

          4. Use of concomitant medications that prolong the QT/QTc interval within 14 days prior
             to Day - 5 to follow-up

          5. Use of a monoamine oxidase inhibitor within 21 days prior to Day 1 to Restabilization.

          6. Received depot neuroleptics unless the last injection was at least 1 treatment cycle
             before Day -5.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Bussel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CCT/Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCT/Parexel</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2010</study_first_submitted>
  <study_first_submitted_qc>February 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <last_update_submitted>September 6, 2011</last_update_submitted>
  <last_update_submitted_qc>September 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lithium DDI with Lurasidone HCl</keyword>
  <keyword>Male/Female, Schizophrenia Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

